Literature DB >> 916091

Ureteral obstruction from prostatic carcinoma: response to endocrine and radiation therapy.

S Michigan, W J Catalona.   

Abstract

Ureteral obstruction occurred in 10% of the patients treated for prostatic carcinoma and most often was associated with poorly differentiated tumors. The response of ureteral obstruction to different forms of therapy was evaluated. Obstruction diminished in 22 of 25 orchiectomized patients (88%) but in only 1 of 6 patients receiving estrogen or antiandrogen therapy alone (17%). Patients who responded favorably to therapy had a significantly better survival than did non-responders. Patients treated early in the course of ureteral obstruction responded better than those treated late, while neither tumor stage nor grade correlated with response to therapy. Radiation therapy for endocrine-resistant ureteral obstruction was effective in only 2 of 8 cases (25%). The literature on ureteral obstruction from prostatic carcinoma and its treatment is reviewed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 916091     DOI: 10.1016/s0022-5347(17)58177-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  [Treatment of specific complications of locally advanced prostate cancer].

Authors:  F C von Rundstedt; A S Brandt; D Lazica; M J Mathers; S Roth
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

2.  Efficacy of orchiectomy versus high dose polyoestradiol phosphate (160 mg) in relieving infravesical obstruction in patients with prostatic cancer.

Authors:  J Aro; R Haapiainen; S Rannikko; O Alfthan
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

3.  Adenocarcinoma of the prostate in perspective.

Authors:  A W Bruce; D E Mahan
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

4.  Acute renal failure secondary to bilateral ureteric obstruction: review of 50 cases.

Authors:  R W Norman; F G Mack; S A Awad; P Belitsky; R D Schwarz; S G Lannon
Journal:  Can Med Assoc J       Date:  1982-10-01       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.